Celgene (CELG) Misses Q4 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- Supermicro raises Q1 FY2027 revenue outlook on AI demand
- Dow outperforms as Wall Street rises, healthcare stocks lead gains
- Crude Inventory Fell 3.06 Million Barrels Last Week - EIA
Jefferies Cuts Price Target on Celgene (CELG) as FX Weighs on Near-Term
January 29, 2016 9:07 AM ESTJefferies maintained a Buy rating on Celgene (NASDAQ: CELG), and cut the price target to $146.00 (from $149.00), following the company's 4Q earnings report. FX volatility appears to be weighing a bit on near-term performance prospects. CELG noted that the ~$700-800M negative top-line impact... More



